End-of-day quote
INDONESIA S.E.
23:00:00 13/05/2024 BST
|
5-day change
|
1st Jan Change
|
3,020
IDR
|
+0.67%
|
|
-4.13%
|
-44.07%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,393,750
|
3,046,875
|
8,625,000
|
5,250,000
|
5,062,500
|
2,831,250
|
-
|
-
|
Enterprise Value (EV)
2 |
3,394
|
1,956
|
7,150
|
4,083
|
5,062
|
1,892
|
1,879
|
2,831
|
P/E ratio
|
16.1
x
|
11.3
x
|
13.9
x
|
14.2
x
|
19.5
x
|
7.71
x
|
7.61
x
|
-
|
Yield
|
3.1%
|
3.45%
|
1.87%
|
7.1%
|
-
|
6.88%
|
8.57%
|
-
|
Capitalization / Revenue
|
1.95
x
|
1.63
x
|
3.25
x
|
2.41
x
|
2.28
x
|
1.21
x
|
1.08
x
|
-
|
EV / Revenue
|
1.95
x
|
1.04
x
|
2.7
x
|
1.87
x
|
2.28
x
|
0.81
x
|
0.71
x
|
-
|
EV / EBITDA
|
12
x
|
5.3
x
|
8.69
x
|
7.96
x
|
10.7
x
|
3.4
x
|
2.82
x
|
-
|
EV / FCF
|
-
|
6.5
x
|
10.6
x
|
12.5
x
|
-
|
8.22
x
|
6.41
x
|
8.61
x
|
FCF Yield
|
-
|
15.4%
|
9.41%
|
7.98%
|
-
|
12.2%
|
15.6%
|
11.6%
|
Price to Book
|
2.04
x
|
1.7
x
|
3.83
x
|
2.27
x
|
-
|
1.13
x
|
1.05
x
|
-
|
Nbr of stocks (in thousands)
|
937,500
|
937,500
|
937,500
|
937,500
|
937,500
|
937,500
|
-
|
-
|
Reference price
3 |
3,620
|
3,250
|
9,200
|
5,600
|
5,400
|
3,020
|
3,020
|
3,020
|
Announcement Date
|
10/03/20
|
12/03/21
|
15/03/22
|
15/03/23
|
08/03/24
|
-
|
-
|
-
|
1IDR in Million2IDR in Billions3IDR Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,744
|
1,873
|
2,652
|
2,182
|
2,222
|
2,347
|
2,632
|
-
|
EBITDA
1 |
283.2
|
369.3
|
822.6
|
513.1
|
474.6
|
556.4
|
665.9
|
-
|
EBIT
1 |
216
|
301.8
|
756.6
|
447
|
299.1
|
423.6
|
483.8
|
-
|
Operating Margin
|
12.39%
|
16.11%
|
28.53%
|
20.49%
|
13.46%
|
18.05%
|
18.38%
|
-
|
Earnings before Tax (EBT)
1 |
264.8
|
339.1
|
786.6
|
470.3
|
338.9
|
468
|
474
|
-
|
Net income
1 |
210.3
|
268.7
|
621.6
|
371.6
|
259.9
|
367
|
372
|
-
|
Net margin
|
12.05%
|
14.35%
|
23.44%
|
17.04%
|
11.69%
|
15.64%
|
14.13%
|
-
|
EPS
2 |
224.3
|
286.7
|
663.1
|
394.9
|
277.2
|
391.8
|
397.0
|
-
|
Free Cash Flow
3 |
-
|
301,134
|
673,159
|
325,985
|
-
|
230,000
|
293,000
|
329,000
|
FCF margin
|
-
|
16,074.41%
|
25,380.61%
|
14,942.19%
|
-
|
9,800.98%
|
11,133.01%
|
-
|
FCF Conversion (EBITDA)
|
-
|
81,533.23%
|
81,830.9%
|
63,538.52%
|
-
|
41,336.72%
|
44,003.27%
|
-
|
FCF Conversion (Net income)
|
-
|
112,051.11%
|
108,290.56%
|
87,713.61%
|
-
|
62,670.3%
|
78,763.44%
|
-
|
Dividend per Share
2 |
112.1
|
112.1
|
172.0
|
397.8
|
-
|
207.7
|
258.7
|
-
|
Announcement Date
|
10/03/20
|
12/03/21
|
15/03/22
|
15/03/23
|
08/03/24
|
-
|
-
|
-
|
1IDR in Billions2IDR3IDR in Million Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
1,091
|
1,475
|
1,167
|
-
|
940
|
952
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
2 |
-
|
301,134
|
673,159
|
325,985
|
-
|
230,000
|
293,000
|
329,000
|
ROE (net income / shareholders' equity)
|
13.1%
|
13.5%
|
30.8%
|
16.1%
|
-
|
14.6%
|
15.4%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
12%
|
25.1%
|
13.8%
|
-
|
12.8%
|
12.2%
|
-
|
Assets
1 |
-
|
2,240
|
2,475
|
2,686
|
-
|
2,867
|
3,049
|
-
|
Book Value Per Share
3 |
1,770
|
1,908
|
2,402
|
2,462
|
-
|
2,665
|
2,886
|
-
|
Cash Flow per Share
3 |
-
|
464.0
|
829.0
|
459.0
|
-
|
518.0
|
553.0
|
-
|
Capex
1 |
-
|
133
|
104
|
134
|
-
|
266
|
255
|
-
|
Capex / Sales
|
-
|
7.13%
|
3.93%
|
6.13%
|
-
|
11.34%
|
9.69%
|
-
|
Announcement Date
|
10/03/20
|
12/03/21
|
15/03/22
|
15/03/23
|
08/03/24
|
-
|
-
|
-
|
1IDR in Billions2IDR in Million3IDR Last Close Price
3,020
IDR Average target price
6,233
IDR Spread / Average Target +106.40% Consensus |
1st Jan change
|
Capi.
|
---|
| -44.07% | 175M | | -15.87% | 8.58B | | +63.16% | 4.12B | | -3.34% | 2.48B | | -9.81% | 2.44B | | -43.01% | 2.29B | | -4.82% | 2B | | -18.74% | 1.53B | | -40.24% | 1.21B | | +9.42% | 1.12B |
Medical & Diagnostic Laboratories
|